Psychiatric medication management for Deerfield Beach — measurement-based, in-person.

Deerfield Beach residents reach RECO Integrated Psychiatry's Delray Beach office in about 22 minutes via A1A or Federal Highway. What clients get is a 60-to-90-minute initial evaluation with a board-certified psychiatrist, a written DSM-5-TR formulation, and medication decisions anchored to PHQ-9 and GAD-7 trajectories rather than a 15-minute impression. When a first-line SSRI does not produce remission, RECO moves through augmentation, class switching, pharmacogenomic testing, and interventional treatment - not another reflexive dose bump.

Deerfield Beach sits 13 miles south of RECO Integrated Psychiatry’s Delray Beach office — roughly 22 minutes up A1A depending on how the Hillsboro bridge is running. Residents of The Cove, Pioneer Park, Hillsboro Beach, Cresthaven, and Goldcoast Centre routinely make the drive because outpatient specialty psychiatry with genuine medication depth is thin on the ground between Boca Raton and Fort Lauderdale. What follows is the clinical work that actually happens in the room — not a description of services, but a description of the standard of care.

What a real psychiatric evaluation actually covers

Initial evaluations at RECO run 60 to 90 minutes and produce a documented DSM-5-TR diagnostic formulation — not a checklist of symptoms and a starter prescription. The intake reconstructs every prior medication trial with specific doses, durations, response, and reason for discontinuation, because “sertraline didn’t work” at 25 mg for two weeks is a different data point than a failed trial at 200 mg over ten weeks. Family psychiatric history, developmental history where relevant, medical comorbidities, and a substance use screen are documented in the same visit.

Anyone presenting with “depression” is screened for bipolar spectrum illness with the MDQ and a careful hypomania history — antidepressant monotherapy in an undiagnosed bipolar patient is one of the more common iatrogenic injuries in outpatient practice. Anyone presenting with “anxiety” is screened for ADHD with the ASRS and for OCD with the Y-BOCS, because the treatment algorithms diverge sharply. Trauma history is elicited where clinically indicated, and suicide risk is documented on the Columbia scale.

Baseline laboratory work — CBC, CMP, TSH, B12 and folate, vitamin D, and a lipid panel — is ordered where the history warrants it. Untreated hypothyroidism, iron deficiency, and vitamin D deficiency masquerade as treatment-resistant depression more often than clinicians care to admit. This is the visit that a 15-minute primary-care slot cannot produce.

Measurement-based care and why it changes outcomes

Every visit is anchored to standardized scales completed before the client walks in: PHQ-9 for depressive symptoms, GAD-7 for anxiety, MDQ for bipolar screening, ASRS for adult ADHD, Y-BOCS for OCD, and PCL-5 for PTSD. Scores are graphed longitudinally in the chart. Medication decisions are pegged to the trajectory of that graph rather than to a subjective “how are you feeling today,” which is confounded by recency effects, sleep, and the weather.

The evidence base is unambiguous — measurement-based care produces measurably higher remission rates and shorter time-to-response than clinical impression alone. A PHQ-9 that has moved from 18 to 14 over six weeks means something different than one stuck at 18, and the medication conversation changes accordingly. The graph also protects clients from the opposite error: staying on a drug that isn’t working because the visit “felt fine.”

The pharmacologic toolkit beyond the first two SSRIs

First-line pharmacotherapy is not controversial. SSRIs and SNRIs — sertraline, escitalopram, duloxetine, venlafaxine — for unipolar depression and most anxiety presentations. Stimulants (mixed amphetamine salts, methylphenidate) and non-stimulants (atomoxetine, guanfacine) for ADHD. Mood stabilizers (lithium, lamotrigine, valproate) and atypicals (quetiapine, aripiprazole, lurasidone) for bipolar disorder. SSRIs at anti-obsessional doses paired with ERP referral for OCD. Prazosin for PTSD nightmares.

The value of specialty psychiatry is what happens after first-line fails or partially responds. Augmentation with aripiprazole, low-dose lithium, or triiodothyronine for partial responders. Switching within class versus across class based on receptor profile and prior side-effect pattern. Buspirone augmentation for residual anxiety. Pharmacogenomic testing (GeneSight, Genomind) in cases where two or three failed trials suggest an atypical metabolizer phenotype. MAOIs — tranylcypromine, phenelzine — where indicated and with the required dietary counseling. Escalation to interventional treatment — medication management coordinated with rTMS or intranasal esketamine (Spravato) — when three adequate pharmacologic trials have not produced remission.

The algorithm has fifteen or twenty steps, not two, and RECO’s psychiatrists move through them.

Monitoring: the labs, the metabolic panel, the drug levels

Lithium requires a baseline TSH, creatinine, and calcium, a 12-hour trough level within a week of any dose change, and quarterly monitoring thereafter — plus vigilance for the slow creep of nephrogenic diabetes insipidus over years. Atypical antipsychotics — olanzapine, quetiapine, risperidone — require baseline and annual metabolic panels including HbA1c, fasting lipids, weight, and blood pressure, per ADA and APA consensus. Weight is tracked at every visit, not just when the client mentions it.

Valproate requires baseline LFTs, CBC with platelets, and levels drawn to a target range. Lamotrigine requires a documented slow titration and explicit rash counseling. Stimulants require a cardiovascular history, resting blood pressure at every visit, and an EKG where family history or exam findings warrant it. Clozapine, when indicated, requires REMS enrollment and the appropriate ANC monitoring cadence.

None of this is optional, and none of it depends on the client remembering to ask. RECO’s protocol builds monitoring into the visit cadence at the time of prescription.

What to expect on your first visit

Clients complete the PHQ-9, GAD-7, and any indicated screening instruments online before arrival. The visit itself is 60 to 90 minutes with a board-certified psychiatrist — not a nurse-practitioner triage followed by a physician signature. The output is a written formulation, a treatment plan with a specific medication or medication change, and a follow-up interval anchored to the half-life of the drug and the acuity of the presentation. Follow-ups are typically 30 minutes, more frequent early in a titration.

Where psychotherapy is indicated — and it usually is — RECO coordinates with CBT, DBT, EMDR, ACT, or MI-trained therapists in the network or in the client’s existing care team. Medication is one lever; combined treatment consistently outperforms either alone in the depression and anxiety literature.

Insurance and admissions from Deerfield Beach

RECO Integrated Psychiatry accepts Florida Blue, Aetna, Cigna, UnitedHealthcare, Humana, and BCBS PPO plans. Benefits are verified before the first visit and out-of-pocket estimates are provided in writing rather than after the fact. Deerfield Beach residents typically reach the Delray Beach office in 22 minutes via Federal Highway or A1A; evening appointments are available for clients whose workday cannot accommodate a mid-afternoon visit, and telepsychiatry follow-ups are offered after the initial in-person evaluation for stable clients on a maintenance dose.

Serving residents of: The Cove, Pioneer Park, Hillsboro Beach, Cresthaven, Goldcoast Centre.